Alnylam Pharmace. buy Subdi
Summary
This prediction ended on 06.09.18 with a price of €105.44. With a performance of -4.71%, the BUY prediction by Subdi finished with a loss. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 6.515% | 6.515% | -9.661% | 42.520% |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % | 52,38 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % | 72,45 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % | 57,58 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % | 62,15 % |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von stratec zu
Subdi stimmt am 31.08.2018 der Buy-Einschätzung von stratec mit dem Kursziel 146,78$ zu.
Überschrift: Alnylam with its first new drug application and multiple clinical read-outs in 2018
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
27.10.18
08.11.18
08.11.18
Alnylam Pharmace.
10.09.18
12.09.18
12.09.18